The Pharmaceutical Journal
Vol 277 No 7407 p6
1 July 2006

This article
Reprint   Photocopy

  Acrobat Reader

Rituximab limits joint damage

Rituximab plus methotrexate is associated with significant inhibition of joint structural damage in rheumatoid arthritis patients with inadequate response to one or more tumour necrosis factor inhibitors, according to data presented at the Annual European Congress of Rheumatology in Amsterdam last week. After one year, bone erosions in the rituximab group (n=272) were reduced by over a half compared with the placebo group (n=184).